These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21275816)

  • 1. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease.
    Rahmadi A; Steiner N; Münch G
    Clin Chem Lab Med; 2011 Mar; 49(3):385-91. PubMed ID: 21275816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?
    Krautwald M; Münch G
    Exp Gerontol; 2010 Oct; 45(10):744-51. PubMed ID: 20211718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
    Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
    Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts.
    Münch G; Schinzel R; Loske C; Wong A; Durany N; Li JJ; Vlassara H; Smith MA; Perry G; Riederer P
    J Neural Transm (Vienna); 1998; 105(4-5):439-61. PubMed ID: 9720973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".
    Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B
    Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.
    Lüth HJ; Ogunlade V; Kuhla B; Kientsch-Engel R; Stahl P; Webster J; Arendt T; Münch G
    Cereb Cortex; 2005 Feb; 15(2):211-20. PubMed ID: 15238435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation endproducts in ageing and Alzheimer's disease.
    Münch G; Thome J; Foley P; Schinzel R; Riederer P
    Brain Res Brain Res Rev; 1997 Feb; 23(1-2):134-43. PubMed ID: 9063589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease.
    Morcos M; Hutter H
    J Alzheimers Dis; 2009; 16(4):897-908. PubMed ID: 19387121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β metabolite sensing: biochemical linking of glycation modification and misfolding.
    Fawver JN; Schall HE; Petrofes Chapa RD; Zhu X; Murray IV
    J Alzheimers Dis; 2012; 30(1):63-73. PubMed ID: 22406446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
    Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
    Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis.
    Schmitt HP
    Med Hypotheses; 2006; 66(5):898-906. PubMed ID: 16442744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in Alzheimer's disease hippocampus: a topographical study.
    Cruz-Sánchez FF; Gironès X; Ortega A; Alameda F; Lafuente JV
    J Neurol Sci; 2010 Dec; 299(1-2):163-7. PubMed ID: 20863531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease--a target for neuroprotective treatment strategies?
    Münch G; Deuther-Conrad W; Gasic-Milenkovic J
    J Neural Transm Suppl; 2002; (62):303-7. PubMed ID: 12456073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-AGEing defences against Alzheimer's disease.
    Münch G; Kuhla B; Lüth HJ; Arendt T; Robinson SR
    Biochem Soc Trans; 2003 Dec; 31(Pt 6):1397-9. PubMed ID: 14641072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease.
    Münch G; Gasic-Milenkovic J; Arendt T
    J Neural Transm Suppl; 2003; (65):63-71. PubMed ID: 12946049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.